JP2005528099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528099A5 JP2005528099A5 JP2004508275A JP2004508275A JP2005528099A5 JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5 JP 2004508275 A JP2004508275 A JP 2004508275A JP 2004508275 A JP2004508275 A JP 2004508275A JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- light chain
- variable domain
- domain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102400000401 Latency-associated peptide Human genes 0.000 claims 4
- 101800001155 Latency-associated peptide Proteins 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36499102P | 2002-03-13 | 2002-03-13 | |
| US42628602P | 2002-11-13 | 2002-11-13 | |
| PCT/US2003/008048 WO2003100033A2 (en) | 2002-03-13 | 2003-03-13 | ANTI-αvβ6 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009011451A Division JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528099A JP2005528099A (ja) | 2005-09-22 |
| JP2005528099A5 true JP2005528099A5 (OSRAM) | 2006-04-27 |
| JP4473117B2 JP4473117B2 (ja) | 2010-06-02 |
Family
ID=29586753
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508275A Expired - Fee Related JP4473117B2 (ja) | 2002-03-13 | 2003-03-13 | 抗αｖβ６抗体 |
| JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
| JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αｖβ６抗体 |
| JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αｖβ６抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αｖβ６抗体 |
| JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αｖβ６抗体 |
| JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αｖβ６抗体 |
| JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αｖβ６抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7465449B2 (OSRAM) |
| EP (4) | EP2336185A1 (OSRAM) |
| JP (6) | JP4473117B2 (OSRAM) |
| KR (1) | KR101098109B1 (OSRAM) |
| CN (4) | CN102924598B (OSRAM) |
| AR (1) | AR038970A1 (OSRAM) |
| AU (1) | AU2003261071C1 (OSRAM) |
| BR (1) | BRPI0308585B8 (OSRAM) |
| CA (1) | CA2478833C (OSRAM) |
| CL (8) | CL2010000792A1 (OSRAM) |
| EA (1) | EA011853B1 (OSRAM) |
| ES (1) | ES2389037T3 (OSRAM) |
| HK (1) | HK1213007A1 (OSRAM) |
| IL (4) | IL164021A0 (OSRAM) |
| IS (1) | IS7443A (OSRAM) |
| ME (1) | ME00804B (OSRAM) |
| MX (1) | MXPA04008870A (OSRAM) |
| MY (2) | MY147019A (OSRAM) |
| NO (1) | NO334834B1 (OSRAM) |
| NZ (2) | NZ535425A (OSRAM) |
| PL (1) | PL216223B1 (OSRAM) |
| RS (1) | RS52488B (OSRAM) |
| WO (1) | WO2003100033A2 (OSRAM) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY147019A (en) * | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| CA2481922A1 (en) * | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| CA2434668A1 (en) | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
| AU2012258386B2 (en) * | 2005-07-08 | 2014-08-07 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| WO2007084570A2 (en) * | 2006-01-17 | 2007-07-26 | Biosite Incorporated | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis |
| CN101563105B (zh) * | 2006-07-10 | 2013-01-23 | 拜奥根Idec马萨诸塞公司 | 用于抑制smad4-缺陷癌症的组合物和方法 |
| WO2008112004A2 (en) * | 2006-08-03 | 2008-09-18 | Astrazeneca Ab | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF |
| AU2007354317A1 (en) * | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
| US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| CA2724432A1 (en) * | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| BRPI0819312A2 (pt) | 2007-11-16 | 2020-09-15 | The Rockefeller University | específico anticorpo para a forma protofibril de proteínas amilóide beta |
| EP2279207B1 (en) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
| CA2723842A1 (en) * | 2008-05-09 | 2009-11-12 | Peter Vanlandschoot | Amino acid sequences directed against integrins and uses thereof |
| ES2607851T3 (es) * | 2008-05-15 | 2017-04-04 | The University Of North Carolina At Chapel Hill | Objetivos novedosos para la regulación de la angiogénesis |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| AU2010285265B2 (en) | 2009-08-19 | 2015-05-21 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in FFPE material |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| EP2563813B1 (en) * | 2010-04-30 | 2015-08-26 | Alexion Pharmaceuticals, Inc. | Anti-c5a antibodies and methods for using the antibodies |
| CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| BR112014019861A2 (pt) | 2012-02-17 | 2017-07-04 | Seattle Genetics Inc | anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| EP2905335B1 (en) * | 2012-10-03 | 2018-01-31 | Chiome Bioscience Inc. | Anti-human dlk-1 antibody having anti-tumor activity in vivo |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| LT3038650T (lt) | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
| KR102150616B1 (ko) | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| EP3052523B1 (en) * | 2013-10-01 | 2021-03-10 | Medimmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| EP3052522B1 (en) | 2013-10-03 | 2019-12-11 | Biocare Medical, LLC | Anti-sox10 antibody systems and methods |
| CN109908017A (zh) | 2013-12-19 | 2019-06-21 | 高露洁-棕榄公司 | 口腔护理组合物 |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| WO2015113169A1 (en) * | 2014-02-03 | 2015-08-06 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| TN2016000525A1 (en) | 2014-05-29 | 2018-04-04 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| AU2016282724A1 (en) | 2015-06-23 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of KSP inhibitors |
| JP6913078B2 (ja) * | 2015-08-13 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| EP3349796A4 (en) | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| US20190144547A1 (en) * | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| US20190284259A1 (en) * | 2016-07-22 | 2019-09-19 | Georgia State University Research Foundation | Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| TW201834710A (zh) | 2016-12-14 | 2018-10-01 | 美商寶珍那提公司 | 以整合素抑制劑治療胃腸道疾病 |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| GB201720989D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| AU2019267166C1 (en) | 2018-05-11 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Furin inhibitors |
| BR112020023846A2 (pt) | 2018-05-23 | 2021-04-13 | Adc Therapeutics Sa | Adjuvante molecular |
| WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| WO2020210358A1 (en) * | 2019-04-08 | 2020-10-15 | Biogen Ma Inc. | Anti-integrin antibodies and uses thereof |
| GB201908536D0 (en) | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
| EP4065167A4 (en) * | 2019-11-26 | 2024-03-27 | Children's Hospital Medical Center | CELA-1 INHIBITION FOR THE TREATMENT OF LUNG DISEASE |
| AU2020397070A1 (en) | 2019-12-05 | 2022-07-14 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| US20240425601A1 (en) * | 2021-01-26 | 2024-12-26 | The Regents Of The University Of California | Compositions and methods for treating and preventing disease associated with avb8 integrin |
| US20240307374A1 (en) | 2021-02-03 | 2024-09-19 | Bp Asset V. Inc. | Formulation of furin inhibitor for inhalation |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
| WO2024263932A2 (en) | 2023-06-23 | 2024-12-26 | Mythic Therapeutics, Inc. | Itgb6-binding proteins and uses thereof |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6417324B1 (en) * | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
| SI0719859T1 (en) | 1994-12-20 | 2003-12-31 | Merck Patent Gmbh | Anti-alpha V-integrin monoclonal antibody |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2229140A1 (en) | 1995-08-17 | 1997-02-27 | Protein Design Labs, Inc. | Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| ATE352613T1 (de) | 1995-08-29 | 2007-02-15 | Kirin Brewery | Chimäres tier und methode zu dessen herstellung |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| ATE248192T1 (de) * | 1996-06-07 | 2003-09-15 | Neorx Corp | HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN |
| AU6721696A (en) | 1996-07-15 | 1998-03-06 | Human Genome Sciences, Inc. | Cd44-like protein |
| US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| NZ515955A (en) | 1997-08-08 | 2003-04-29 | Univ California | Hybridoma producing a monoclonal antibody against beta-6 integrin |
| SK10772000A3 (sk) * | 1998-01-23 | 2001-01-18 | Merck Patent Gmbh | Monoklonálna protilátka anti alfa v-integrín, jej fragment, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie |
| CN1335853A (zh) | 1998-12-19 | 2002-02-13 | 默克专利股份公司 | 整联蛋白αvβb的抑制剂 |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| BRPI0209792B8 (pt) | 2001-04-13 | 2021-05-25 | Biogen Idec Inc | anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina |
| DE10118550A1 (de) | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
| GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| KR20040105740A (ko) | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| MY147019A (en) | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| CA2481922A1 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US20040038856A1 (en) | 2002-05-17 | 2004-02-26 | Sarvajit Chakravarty | Treatment of fibroproliferative disorders using TGF-beta inhibitors |
| KR20110140143A (ko) | 2002-11-26 | 2011-12-30 | 애보트 바이오테라퓨틱스 코포레이션 | 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체 |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| ES2308227T3 (es) | 2003-10-01 | 2008-12-01 | Merck Patent Gmbh | Antagonistas de integrina alfavbeta3 y alfavbeta6 como agentes antifibroticos. |
| US20070292887A1 (en) | 2003-11-04 | 2007-12-20 | Bayer Pharmaceuticals Corporation | Immunohistochemical Methods |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CN101563105B (zh) | 2006-07-10 | 2013-01-23 | 拜奥根Idec马萨诸塞公司 | 用于抑制smad4-缺陷癌症的组合物和方法 |
| AU2007354317A1 (en) | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
| GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
| CA2747937C (en) | 2008-12-23 | 2019-02-26 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2013148316A1 (en) | 2012-03-29 | 2013-10-03 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
-
2003
- 2003-03-13 MY MYPI20030886A patent/MY147019A/en unknown
- 2003-03-13 ES ES03755325T patent/ES2389037T3/es not_active Expired - Lifetime
- 2003-03-13 MX MXPA04008870A patent/MXPA04008870A/es active IP Right Grant
- 2003-03-13 EP EP10012545A patent/EP2336185A1/en not_active Withdrawn
- 2003-03-13 RS YU80704A patent/RS52488B/sr unknown
- 2003-03-13 WO PCT/US2003/008048 patent/WO2003100033A2/en not_active Ceased
- 2003-03-13 NZ NZ535425A patent/NZ535425A/en not_active IP Right Cessation
- 2003-03-13 KR KR1020047014307A patent/KR101098109B1/ko not_active Expired - Lifetime
- 2003-03-13 MY MYPI20094390A patent/MY154009A/en unknown
- 2003-03-13 CN CN201210067222.6A patent/CN102924598B/zh not_active Expired - Lifetime
- 2003-03-13 EA EA200401198A patent/EA011853B1/ru unknown
- 2003-03-13 BR BRPI0308585A patent/BRPI0308585B8/pt not_active IP Right Cessation
- 2003-03-13 AR ARP030100885A patent/AR038970A1/es not_active Application Discontinuation
- 2003-03-13 IL IL16402103A patent/IL164021A0/xx unknown
- 2003-03-13 PL PL372662A patent/PL216223B1/pl unknown
- 2003-03-13 AU AU2003261071A patent/AU2003261071C1/en not_active Expired
- 2003-03-13 ME MEP-2009-200A patent/ME00804B/me unknown
- 2003-03-13 CA CA2478833A patent/CA2478833C/en not_active Expired - Lifetime
- 2003-03-13 EP EP10013156.4A patent/EP2287199B1/en not_active Expired - Lifetime
- 2003-03-13 JP JP2004508275A patent/JP4473117B2/ja not_active Expired - Fee Related
- 2003-03-13 CN CNA038089068A patent/CN1646160A/zh active Pending
- 2003-03-13 US US10/507,662 patent/US7465449B2/en not_active Expired - Lifetime
- 2003-03-13 CN CN2012100664380A patent/CN102659946A/zh active Pending
- 2003-03-13 EP EP10013155A patent/EP2287198A3/en not_active Ceased
- 2003-03-13 EP EP03755325A patent/EP1490110B1/en not_active Expired - Lifetime
- 2003-03-13 CN CN201510182148.6A patent/CN104805090A/zh active Pending
- 2003-12-13 NZ NZ563951A patent/NZ563951A/en not_active IP Right Cessation
-
2004
- 2004-09-09 IS IS7443A patent/IS7443A/is unknown
- 2004-09-12 IL IL225633A patent/IL225633B/en unknown
- 2004-09-12 IL IL164021A patent/IL164021A/en active IP Right Grant
- 2004-10-13 NO NO20044347A patent/NO334834B1/no not_active IP Right Cessation
-
2008
- 2008-10-29 US US12/260,510 patent/US8153126B2/en not_active Expired - Lifetime
-
2009
- 2009-01-21 JP JP2009011451A patent/JP2009100763A/ja not_active Withdrawn
-
2010
- 2010-07-23 CL CL2010000792A patent/CL2010000792A1/es unknown
- 2010-07-23 CL CL2010000790A patent/CL2010000790A1/es unknown
- 2010-07-23 CL CL2010000791A patent/CL2010000791A1/es unknown
- 2010-07-23 CL CL2010000787A patent/CL2010000787A1/es unknown
- 2010-07-23 CL CL2010000785A patent/CL2010000785A1/es unknown
- 2010-07-23 CL CL2010000786A patent/CL2010000786A1/es unknown
- 2010-07-23 CL CL2010000788A patent/CL2010000788A1/es unknown
- 2010-07-23 CL CL2010000789A patent/CL2010000789A1/es unknown
-
2012
- 2012-04-10 US US13/443,261 patent/US20120251532A1/en not_active Abandoned
- 2012-08-09 JP JP2012177348A patent/JP5616932B2/ja not_active Expired - Lifetime
- 2012-08-09 JP JP2012177349A patent/JP2012228269A/ja not_active Withdrawn
-
2013
- 2013-04-08 IL IL225633A patent/IL225633A0/en unknown
-
2014
- 2014-07-28 US US14/444,701 patent/US9745376B2/en not_active Expired - Fee Related
- 2014-11-19 JP JP2014234208A patent/JP2015091807A/ja not_active Withdrawn
-
2015
- 2015-03-11 JP JP2015048289A patent/JP2015126743A/ja not_active Withdrawn
-
2016
- 2016-01-22 HK HK16100767.3A patent/HK1213007A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528099A5 (OSRAM) | ||
| ME00804B (me) | Anti-alpha v beta 6 antitela | |
| JP2009541204A5 (OSRAM) | ||
| JP2007536932A5 (OSRAM) | ||
| JP2022079549A5 (OSRAM) | ||
| JP2004517611A5 (OSRAM) | ||
| JP2009517057A5 (OSRAM) | ||
| JP2010523096A5 (OSRAM) | ||
| JP2020514310A5 (OSRAM) | ||
| RU2009101788A (ru) | Направленные на опухоль моноклональные антитела против fzd10 и их применение | |
| JP2005533493A5 (OSRAM) | ||
| JP2005225884A5 (OSRAM) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2019107018A5 (OSRAM) | ||
| JP2008529497A5 (OSRAM) | ||
| JP2020526478A5 (OSRAM) | ||
| JP2010533498A5 (OSRAM) | ||
| JP2006507013A5 (OSRAM) | ||
| JP2012012402A5 (OSRAM) | ||
| JP2011528561A5 (OSRAM) | ||
| JP2010536886A5 (OSRAM) | ||
| RU2012112829A (ru) | Анти-gitr-антитела | |
| RU2015143242A (ru) | Антитела против gdf8 человека | |
| JP2013056885A5 (OSRAM) | ||
| JP2009297037A5 (OSRAM) |